Search
Anavex Life Sciences Corp
AVXLAdd to Watchlist
2.760USD
+0.180+6.98%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
239.21MMarket Cap
LossP/E TTM
More Details of Anavex Life Sciences Corp Company
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Anavex Life Sciences Corp Info
Ticker SymbolAVXL
Company nameAnavex Life Sciences Corp
IPO dateApr 13, 2006
CEOMissling (Christopher U)
Number of employees34
Security typeOrdinary Share
Fiscal year-endApr 13
Address630 5Th Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10111
Phone18446893939
Websitehttps://www.anavex.com
Ticker SymbolAVXL
IPO dateApr 13, 2006
CEOMissling (Christopher U)
Company Executives of Anavex Life Sciences Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Anavex Life Sciences Corp?
The top five shareholders of Anavex Life Sciences Corp are: Dr. Christopher U. Missling, Ph.D.
How many institutions hold shares of Anavex Life Sciences Corp (AVXL)?
As of 2026Q1, 369 institutions hold shares of Anavex Life Sciences Corp, with a combined market value of approximately 37.30M, accounting for 40.25% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1046425.00.